Encoded Therapeutics, a clinical-stage biotechnology company, has raised $275 million in Series F financing, providing the company with substantial new capital to advance its lead program, ETX101, through pivotal development and accelerate its broader neurological disease pipeline.

 

The financing was co-led by GV and another healthcare fund, with participation from ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock.

 

The new funding comes as Encoded moves ETX101 into pivotal development for SCN1A+ Dravet syndrome, a severe form of epilepsy that begins in infancy or early childhood. Proceeds will support a pivotal study in infants and young children, as well as an expansion study enrolling children and adolescents up to 18 years of age.

 

Beyond clinical development, the financing will enable Encoded to scale its internal GMP manufacturing capabilities, strengthening the company’s infrastructure as it advances ETX101 toward potential registration and prepares for the next wave of its precision genetic medicine pipeline.

 

A key part of that pipeline is ETX301, which the company is advancing toward a targeted 2027 Investigational New Drug (IND) submission for post-amputation neuroma pain.

 

The financing follows encouraging interim results from the Phase 1/2 POLARIS study of ETX101, which Encoded recently presented at the European Epilepsy Congress. The company reported substantial and sustained reductions in seizure frequency, alongside encouraging signals of developmental improvement.

 

“The interim Phase 1/2 POLARIS data we recently shared at the European Epilepsy Congress demonstrate substantial and sustained seizure frequency reductions alongside encouraging developmental gains. This progress strengthens our conviction in ETX101 and the potential of our approach to meaningfully alter the course of Dravet syndrome,” said Kartik Ramamoorthi, Chief Executive Officer of Encoded. 

 

“With pivotal development underway, this financing gives us the resources to advance ETX101 toward registration while continuing to build the capabilities and pipeline that will define Encoded’s next stage.”

 

For Encoded, the latest financing marks a significant step from early clinical validation toward potentially transformative late-stage development. The company is positioning ETX101 as the lead asset in a broader strategy to use precision genetic medicines to address the underlying biology of severe neurological disorders.

 

“The emerging clinical profile of ETX101 is increasingly compelling with durable seizure control and promising neurodevelopmental signals, reinforcing its potential as a transformative therapy,” said Brendan Bulik-Sullivan, General Partner at GV. “We are pleased to co-lead this financing and support Encoded as it advances ETX101 through pivotal development.”

 

The investor backing also reflects growing confidence in Encoded’s underlying genetic medicine platform and its potential beyond Dravet syndrome.

 

“Progress with ETX101 provides important validation of Encoded’s differentiated approach to genetic medicine and the broader potential of its platform,” added David Schenkein, General Partner and Co-Lead of Life Sciences at GV.